Menu
Back to User profile » Dr Fernando Martinez
Papers published by Dr Fernando Martinez:
High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis
Archontakis Barakakis P, Tran T, You JY, Hernandez Romero GJ, Gidwani V, Martinez FJ, Fortis S
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:469-482
Published Date: 6 April 2023
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
Maspero JF, Bachert C, Martinez FJ, Hanania NA, Ortiz B, Patel N, Mannent LP, Praestgaard A, Pandit-Abid N, Siddiqui S, Hardin M
Journal of Asthma and Allergy 2023, 16:333-342
Published Date: 31 March 2023
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3061-3073
Published Date: 6 December 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642
Published Date: 25 July 2022
CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
Alves L, Pullen R, Hurst JR, Miravitlles M, Carter V, Chen R, Couper A, Dransfield M, Evans A, Hardjojo A, Jones D, Jones R, Kerr M, Kostikas K, Marshall J, Martinez F, Melle MV, Murray R, Muro S, Nordon C, Pollack M, Price C, Sharma A, Singh D, Winders T, Price DB
Patient Related Outcome Measures 2022, 13:53-68
Published Date: 23 February 2022
Letter to Editor Regarding the OCEAN Study [Letter]
Yawn BP, Make B, Mannino D, Martinez FJ, Han MK
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2501-2502
Published Date: 2 September 2021
CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst JR, Alves L, Dransfield M, Chen R, Muro S, Winders T, Blango C, Muellerova H, Trudo F, Dorinsky P, Alacqua M, Morris T, Carter V, Couper A, Jones R, Kostikas K, Murray R, Price DB
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2301-2322
Published Date: 12 August 2021
Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Zou C, Li F, Choi J, Haghighi B, Choi S, Rajaraman PK, Comellas AP, Newell Jnr JD, Lee CH, Barr RG, Bleecker E, Cooper CB, Couper D, Han M, Hansel NN, Kanner RE, Kazerooni EA, Kleerup EC, Martinez FJ, O'Neal W, Paine III R, Rennard SI, Smith BM, Woodruff PG, Hoffman EA, Lin CL
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1477-1496
Published Date: 31 May 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, Dorinsky P, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:179-189
Published Date: 28 January 2021
Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
Stott-Miller M, Müllerová H, Miller B, Tabberer M, El Baou C, Keeley T, Martinez FJ, Han M, Dransfield M, Hansel NN, Cooper CB, Woodruff P, Ortega VE, Comellas AP, Paine R III, Kanner RE, Anderson W, Drummond MB, Kim V, Tal-Singer R, Lazaar AL
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2467-2476
Published Date: 13 October 2020
Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D, Quibrera M, Criner G, Dransfield MT, Han MK, Hansel NN, Krishnan JA, Lazarus SC, Peters SP, Barr RG, Martinez FJ, Woodruff PG
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1887-1898
Published Date: 4 August 2020
FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
Bikov A, Lange P, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Yates JC, Vestbo J
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1135-1142
Published Date: 20 May 2020
Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis [Corrigendum]
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine III R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:901-902
Published Date: 23 April 2020
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:99-106
Published Date: 9 January 2020
Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine III R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2927-2938
Published Date: 20 December 2019
Effects of baseline symptom burden on treatment response in COPD
Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:181-194
Published Date: 4 January 2019
Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?
Leidy NK, Martinez FJ, Malley KG, Mannino DM, Han MLK, Bacci ED, Brown RW, Houfek JF, Labaki WW, Make BJ, Meldrum CA, Quezada W, Rennard S, Thomashow B, Yawn BP
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1901-1912
Published Date: 13 June 2018
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design
Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1921-1928
Published Date: 17 August 2016